Value of 18F-FDG PET/CT in the evaluation of treatment response and prognosis for patients with recurrent uterine cervical cancer
10.3760/cma.j.issn.2095-2848.2015.03.003
- VernacularTitle:18F-FDG PET/CT在复发宫颈癌疗效评价及预后预测中的价值
- Author:
Dandan CHEN
;
Hubing WU
;
Quanshi WANG
;
Yanjiang HAN
;
Wenlan ZHOU
;
Hongsheng LI
;
Ying TIAN
- Publication Type:Journal Article
- Keywords:
Cervix neoplasms;
Neoplasm recurrence,local;
Prognosis;
Tomography,emission-computed;
Tomography,X-ray computed;
Deoxyglucose
- From:
Chinese Journal of Nuclear Medicine and Molecular Imaging
2015;35(3):168-172
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the value of 18F-FDG PET/CT in the evaluation of treatment response and prognosis for patients.with recurrent uterine cervical cancer.Methods Forty-five patients with recurrent uterine cervical cancer underwent 18F-FDG PET/CT before and after treatment from October 2004 to December 2014,and their PET/CT results were retrospectively analyzed.Treatment response was categorized as complete metabolic response (CMR),partial metabolic response (PMR),stable metabolic disease (SMD) and progressive metabolic disease (PMD) according to PET response criteria in solid tumors (PERCIST).Kaplan-Meier survival analysis was used.The difference of progression-free survival (PFS) between patients with and without PMD was compared by x2 test.The PFS difference among patients with different SUVmax on pretreatment PET/CT was also compared byx2 test.Results After treatment,22.2％ (10/45) of patients were categorized as CMR,22.2％(10/45) as PMR,4.4％(2/45) as SMD and 51.1％ (23/45) as PMD by post-treatment 18F-FDG PET/CT.Thirty-two patients had long-term (6-64 months) clinical follow-up.The PFS was 1-64 months and the median PFS was 5 months.The patients without PMD had a significantly better PFS than those with PMD(12.2 vs 4.2 months,x2 =7.223,P＜0.01).Patients with lesion SUVmax＜7.5 on pretreatment PET/CT had a better PFS than those with SUVmax ≥7.5 (16.3 vs 5.9 months,x2 =5.415,P＜0.05).Conclusion 18F-FDG PET/CT is useful forthe evaluation of treatment response and prognosis in patients with recurrent cancer of the uterine cervix.
